A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.
Also called NCT05318326
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
- Registry
-
NCT05318326
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05318326. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- placebo group
- Intervention (Drug)
- Yogliptin 400mg group
- Intervention (Drug)
- Yogliptin 200mg group
- Lead sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
Record details
- Record id
cardio:ct-nct05318326- Content hash
b766faeb110939c3519f828f53e8d2400fd55860191a3b23a898458b6d5da028